Ditchcarbon
  • Contact
  1. Organizations
  2. Astellas Pharma Ltd.
Public Profile
Pharmaceutical Preparation Manufacturing
GB
updated 8 months ago

Astellas Pharma Ltd. Sustainability Profile

Company website

Astellas Pharma Ltd., a leading global pharmaceutical company headquartered in the United Kingdom, is renowned for its innovative approach to healthcare. Founded in 2005 through the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd., Astellas has established a strong presence in key operational regions, including Europe, North America, and Asia. Specialising in areas such as urology, oncology, and immunology, Astellas is committed to developing unique therapies that address unmet medical needs. The company’s core products, including the prostate cancer treatment Xtandi and the antifungal agent Cresemba, exemplify its dedication to advancing patient care. With a robust pipeline and a focus on research and development, Astellas Pharma Ltd. continues to solidify its position as a prominent player in the global pharmaceutical industry, recognised for its contributions to innovative healthcare solutions.

DitchCarbon Score

How does Astellas Pharma Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

50

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

31

Industry Benchmark

Astellas Pharma Ltd.'s score of 50 is higher than 71% of the industry. This can give you a sense of how well the company is doing compared to its peers.

71%

Let us know if this data was useful to you

Astellas Pharma Ltd.'s reported carbon emissions

Inherited from Astellas Pharma Inc.

Astellas Pharma Ltd., headquartered in Great Britain, currently does not report specific carbon emissions data for the most recent year, as indicated by the absence of emissions figures. The company is a current subsidiary of Astellas Pharma Inc., which may influence its climate commitments and reporting practices. While Astellas Pharma Ltd. has not outlined specific reduction targets or achievements, it is important to note that its climate initiatives and performance metrics are inherited from Astellas Pharma Inc. This includes participation in the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), both of which are critical frameworks for setting and achieving climate goals. As a part of its corporate family, Astellas Pharma Ltd. aligns with broader industry standards and commitments to reduce greenhouse gas emissions, although specific targets and metrics have not been disclosed at this level. The company’s climate strategy may reflect the overarching goals set by its parent organization, Astellas Pharma Inc., which is actively engaged in sustainability efforts. In summary, while Astellas Pharma Ltd. does not provide specific emissions data or reduction targets, it is positioned within a corporate structure that prioritises climate action and sustainability through its affiliation with Astellas Pharma Inc.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

20052011201220132014201520162017201820192020202120222023
Scope 1
108,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
Scope 2
-
00,000,000
000,000,000
000,000,000
000,000,000
000,000,000
-
000,000,000
000,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
Scope 3
-
-
-
-
-
0,000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
0,000,000,000

How Carbon Intensive is Astellas Pharma Ltd.'s Industry?

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Astellas Pharma Ltd.'s primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

How Carbon Intensive is Astellas Pharma Ltd.'s Location?

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Astellas Pharma Ltd. is in GB, which has a very low grid carbon intensity relative to other regions.

Astellas Pharma Ltd.'s Climate Goals (2030 & 2050)

Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.

Astellas Pharma Ltd. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Compare Astellas Pharma Ltd.'s Emissions with Industry Peers

UCB, Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated about 1 month ago

Accord Healthcare, Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated about 1 month ago

Mylan, Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated about 2 months ago

Bristol-Myers Squibb

US
•
Pharmaceutical Preparation Manufacturing
Updated 28 minutes ago

Teva Pharmaceuticals

IL
•
Pharmaceutical Preparation Manufacturing
Updated 10 days ago

Hospira

US
•
Pharmaceutical Preparation Manufacturing
Updated about 2 months ago

Let us know if this data was useful to you

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251030.3
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelog
AboutTeamCareersLicense AgreementPrivacy